{"title":"Does having COVID-19 infection history lead to a different clinical presentation and treatment response in patients with major depression?","authors":"Zehra Gokkaya Kilic , Mustafa Ugurlu , Esra Kabadayi Sahin , Gulsum Zuhal Kamis , Gorkem Karakas Ugurlu , Ali Caykoylu","doi":"10.1016/j.jpsychires.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate whether a history of Coronavirus disease 2019 (COVID-19) affects depression severity, symptoms, and treatment response in patients with major depressive disorder (MDD).</div></div><div><h3>Methods</h3><div>The study included 76 patients with a history of COVID-19 and 98 patients without, all diagnosed with first-episode MDD. After one month, 32 patients with and 36 without a history of COVID-19 were re-evaluated. Beck Depression Inventory, Clinically Useful Depression Outcome Scale, Community Assessment of Psychic Experiences, WHO Quality of Life Scale Short Form, Pittsburgh Sleep Quality Index, and Structured Interview Guide for the Hamilton Depression Rating Scale Seasonal Affective Disorder Version (SIGH-SAD) were administered to the patients at the initial presentation. The self-report scales were re-administered at the follow-up visit.</div></div><div><h3>Results</h3><div>Patients with a history of COVID-19 infection had significantly higher SIGH-SAD scores for increased appetite, weight gain, somatic anxiety, and paranoid symptoms. After treatment, improvement in the physical subscale of quality of life was significantly better in these patients.</div></div><div><h3>Conclusion</h3><div>While depression severity was similar in both groups, atypical symptoms were more prominent in patients with a history of COVID-19 infection. These patients also showed greater improvements in mixed symptoms and quality of life after treatment.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"184 ","pages":"Pages 224-231"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychiatric research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022395625001451","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
This study aimed to investigate whether a history of Coronavirus disease 2019 (COVID-19) affects depression severity, symptoms, and treatment response in patients with major depressive disorder (MDD).
Methods
The study included 76 patients with a history of COVID-19 and 98 patients without, all diagnosed with first-episode MDD. After one month, 32 patients with and 36 without a history of COVID-19 were re-evaluated. Beck Depression Inventory, Clinically Useful Depression Outcome Scale, Community Assessment of Psychic Experiences, WHO Quality of Life Scale Short Form, Pittsburgh Sleep Quality Index, and Structured Interview Guide for the Hamilton Depression Rating Scale Seasonal Affective Disorder Version (SIGH-SAD) were administered to the patients at the initial presentation. The self-report scales were re-administered at the follow-up visit.
Results
Patients with a history of COVID-19 infection had significantly higher SIGH-SAD scores for increased appetite, weight gain, somatic anxiety, and paranoid symptoms. After treatment, improvement in the physical subscale of quality of life was significantly better in these patients.
Conclusion
While depression severity was similar in both groups, atypical symptoms were more prominent in patients with a history of COVID-19 infection. These patients also showed greater improvements in mixed symptoms and quality of life after treatment.
期刊介绍:
Founded in 1961 to report on the latest work in psychiatry and cognate disciplines, the Journal of Psychiatric Research is dedicated to innovative and timely studies of four important areas of research:
(1) clinical studies of all disciplines relating to psychiatric illness, as well as normal human behaviour, including biochemical, physiological, genetic, environmental, social, psychological and epidemiological factors;
(2) basic studies pertaining to psychiatry in such fields as neuropsychopharmacology, neuroendocrinology, electrophysiology, genetics, experimental psychology and epidemiology;
(3) the growing application of clinical laboratory techniques in psychiatry, including imagery and spectroscopy of the brain, molecular biology and computer sciences;